¡Ya estamos en ! Descubre más

GE HealthCare

GEHC

Capitalización de mercado USD 31.4 mil M

69.57 USD

-0.78

1.11%

Al cierre Actualizado 16 oct, 4:00 p.m. EDT

Antes de la apertura del mercado

Después del cierre del mercado

69.50

-0.07

0.1%

1 día

-1.11%

5 días

5.38%

1 mes

9.58%

3 meses

5.89%

6 meses

-4.96%

En lo que va del año

-16%

1 año

-5.19%

5 años

15.95%

10 años

15.95%

Acerca de: GE HealthCare Technologies is a leading medical technology firm with leading market share in imaging and ultrasound equipment. The company reports four major segments: imaging (45% of revenue), advanced visualization solutions (26%), patient care solutions (15%), and pharmaceutical diagnostics (14%). The company's sales are geographically diverse, with the United States, EMEA, China, and the rest of the world accounting for 46%, 26%, 11%, and 17%, respectively. We estimate approximately half of its revenue is recurring, which consists of servicing (about one-third of revenue), pharmaceutical diagnostics (about 10%-15%), and digital solutions (just over 5%).

Empleados: 54,000

Atención médica Dispositivos médicos

Noticias

Positivo

Neutral

Negativo

Sentimiento 3 meses

Positivo 41.8%

Neutral 55.7%

Negativo 2.5%

Research conducted at University of Michigan published in Anesthesia & Analgesia Practice demonstrates GE HealthCare End-tidal Control software may help to reduce fresh gas flow

CHICAGO--(BUSINESS WIRE)--GE HealthCare (Nasdaq: GEHC) today announced the publication of research conducted at the University of Michiganiv evaluating the use of End-tidal Control software across a large multisite academic health system in Anesthesia & Analgesia Practice. The retrospective observational study analyzed 12,818 adult general anesthesia cases performed at University of Michigan Health – Ann Arbor locations between April 1, 2023 and September 30, 2024 on anesthesia machines wit.

Research conducted at University of Michigan published in Anesthesia & Analgesia Practice demonstrates GE HealthCare End-tidal Control software may help to reduce fresh gas flow

GE HealthCare's MINItrace™ Magni achieves CE Mark; Copper-64 expands PETtrace™ Solid Target Platform beyond Gallium-68

CHICAGO--(BUSINESS WIRE)--GE HealthCare (Nasdaq: GEHC) today announced that its MINItrace Magni cyclotron has achieved CE Mark and that its PETtrace Solid Target Platform is expanding beyond Gallium-68 with support for Copper-64 (⁶⁴Cu) production. Together, the developments reflect the company's focus on helping institutions build the production capabilities behind their molecular imaging programs—from establishing local PET radioisotope production to supporting research into emerging radiophar.

GE HealthCare's MINItrace™ Magni achieves CE Mark; Copper-64 expands PETtrace™ Solid Target Platform beyond Gallium-68

The Motley Fool

2 Beaten-Down Healthcare Stocks That Could Soar in the Fourth Quarter

Both Danaher and GE Healthcare are trading at attractive valuations after recent declines. Upcoming earnings reports are key catalysts for potential stock rebounds.

2 Beaten-Down Healthcare Stocks That Could Soar in the Fourth Quarter

GE HealthCare to announce third quarter 2026 results on October 28, 2026

CHICAGO--(BUSINESS WIRE)--GE HealthCare (Nasdaq: GEHC) will announce its third quarter 2026 financial results before the market opens on Wednesday, October 28, 2026. The GE HealthCare management team will also host a conference call and webcast at 8:30 a.m. Eastern Time / 7:30 a.m. Central Time on that same day, which will be a live webcast and accessible at https://investor.gehealthcare.com/news-events/events. The earnings release, accompanying financial information, and webcast replay also wil.

GE HealthCare to announce third quarter 2026 results on October 28, 2026

Zacks Investment Research

GE HealthCare Expands U.S. PET Radiopharma Reach With SOFIE Deal

GEHC's $945M SOFIE Biosciences deal will expand its U.S. PET radiopharmaceutical footprint and boost exposure to precision care growth.

GE HealthCare Expands U.S. PET Radiopharma Reach With SOFIE Deal

Securities Fraud Investigation Into GE HealthCare Technologies Inc. (GEHC) Continues – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm

LOS ANGELES, Oct. 05, 2026 (GLOBE NEWSWIRE) -- Glancy Prongay Wolke & Rotter LLP, a leading national shareholder rights law firm, continues its investigation on behalf of GE HealthCare Technologies Inc. (“GE HealthCare” or the “Company”) (NASDAQ: GEHC) investors concerning the Company's possible violations of the federal securities laws.

Securities Fraud Investigation Into GE HealthCare Technologies Inc. (GEHC) Continues – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm

GE HealthCare to buy Sofie Biosciences for $945 million to strengthen radiopharma business

Medical device maker GE HealthCare said on Monday it would buy privately held Sofie Biosciences for $945 million in cash, in a move that strengthens its ability ‌to manufacture and distribute PET imaging drugs.

GE HealthCare to buy Sofie Biosciences for $945 million to strengthen radiopharma business

GE HealthCare Technologies Inc. (GEHC) Shareholders Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation

BENSALEM, Pa., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Law Offices of Howard G.

GE HealthCare Technologies Inc. (GEHC) Shareholders Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation

GE HealthCare Bets $945M on Fast-Growing Market With Sofie Biosciences Acquisition

GE Healthcare Technologies will purchase radiopharmaceutical company Sofie Biosciences to expand into a lucrative therapeutic area.

GE HealthCare Bets $945M on Fast-Growing Market With Sofie Biosciences Acquisition

GE HealthCare to Acquire SOFIE Biosciences, Establishing a 'Final Mile' Footprint for PET Radiopharmaceutical Supply in the U.S.

CHICAGO--(BUSINESS WIRE)--GE HealthCare (Nasdaq: GEHC) today announced a definitive agreement to acquire SOFIE Biosciences, a leading U.S.-based CMO for PET radiopharmaceuticals, from Trilantic North America, for a purchase price of $945 million paid in cash. The transaction is expected to close in the first half of 2027, subject to closing conditions, including regulatory approvals, at which time SOFIE Biosciences will become part of GE HealthCare's PDx segment. The acquisition of SOFIE Biosci.

GE HealthCare to Acquire SOFIE Biosciences, Establishing a 'Final Mile' Footprint for PET Radiopharmaceutical Supply in the U.S.

Ver rankings de noticias

Gráficos de precios implementados con Lightweight Charts™